Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.
Capricor Therapeutics Inc (NASDAQ: CAPR) generates news primarily around its development of cell and exosome-based therapeutics for rare diseases, with a strong focus on Duchenne muscular dystrophy (DMD). The company’s announcements frequently highlight clinical trial milestones for its lead investigational therapy, Deramiocel (CAP-1002), as well as updates on its StealthX™ exosome platform.
Investors and followers of CAPR news can expect detailed coverage of clinical trial results and regulatory interactions. Recent communications include positive topline results from the pivotal Phase 3 HOPE-3 study of Deramiocel in DMD, information on primary and secondary endpoints such as Performance of Upper Limb (PUL v2.0) and left ventricular ejection fraction, and commentary from clinical investigators. Capricor also reports on its engagement with the U.S. Food and Drug Administration, including a Complete Response Letter for its Biologics License Application and subsequent Type A meeting to align on the role of HOPE-3 data in the regulatory pathway.
News items also cover corporate and financial developments, such as quarterly financial results, public offerings of common stock, and manufacturing readiness at the company’s GMP facility in San Diego, California. In addition, Capricor issues updates on scientific publications and conference presentations, including peer-reviewed work describing Deramiocel’s mechanism of action and data on scalable loading of therapeutic oligonucleotides into exosomes.
For those tracking CAPR, this news feed provides a centralized view of clinical, regulatory, scientific and financing updates directly related to Capricor’s programs. Regular review of these items can help readers follow the progress of Deramiocel in DMD, developments in the StealthX™ platform, and key corporate decisions that shape the company’s therapeutic pipeline.
Nippon Shinyaku Co., Ltd. and Capricor Therapeutics have formed an exclusive distribution agreement for CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD) in the U.S. This investigational therapy is not yet approved in the U.S. CAP-1002 uses human cardiosphere-derived cells, targeting a range of DMD patients. A Phase II trial showed promise in enhancing upper limb and cardiac functions. The drug has received orphan and RMAT designations from the FDA, paving the way for a Phase III trial, with a potential market launch post-BLA approval.
Capricor Therapeutics (NASDAQ: CAPR) has partnered with Nippon Shinyaku for the exclusive commercialization of its lead asset, CAP-1002, for Duchenne muscular dystrophy (DMD) in the U.S. Capricor will receive an upfront payment of $30 million and potential milestone payments of up to $705 million. The HOPE-3 Phase 3 trial has been approved by the FDA and is set to begin. Capricor will maintain a double-digit revenue percentage from product sales. The collaboration aims to leverage Nippon Shinyaku's expertise in rare diseases and existing DMD treatment portfolio.
Capricor Therapeutics (NASDAQ: CAPR) announced significant progress in its COVID-19 therapeutic development. A study published in the Journal of Biological Chemistry indicates that its exosome-based mRNA vaccine candidate can generate a robust T-cell response, potentially offering long-lasting immunity. Capricor has also completed enrollment for its Phase 2 trial of CAP-1002, aimed at treating severe COVID-19 patients, with topline data expected in Q1 2022. The dual mRNA delivery method could enhance protection against coronavirus variants, showcasing the company's innovative approach to addressing the pandemic.
Capricor Therapeutics (NASDAQ: CAPR) announced that CEO Dr. Linda Marbán will be the keynote speaker at the TriLink Biotechnologies Annual mRNA Day Conference on November 16, 2021. The global virtual event, in collaboration with Genetic Engineering News and The CRISPR Journal, aims to explore advancements in mRNA-based therapeutics. Dr. Marbán emphasized the importance of mRNA technology in treating diseases, particularly post-COVID-19. Capricor continues to develop its leading candidate, CAP-1002, and exosome technology for various diseases.
Capricor Therapeutics has announced significant progress in its clinical programs, including the approval of the Phase 3 HOPE-3 study for CAP-1002 in Duchenne muscular dystrophy (DMD). The positive Phase 2 HOPE-2 data, which met its primary efficacy endpoint with a p-value of 0.01, demonstrated a 71% slowing in disease progression. Additionally, the INSPIRE trial for COVID-19 has completed enrollment with 63 patients. Financially, the company reported a net loss of $3.9 million for Q3 2021, with $40.8 million in cash reserves, sufficient to support operations for two more years.
Capricor Therapeutics (NASDAQ: CAPR) will announce its third quarter financial results on November 9, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET. The company focuses on developing cell and exosome-based therapeutics, with its lead candidate, CAP-1002, in clinical trials for Duchenne muscular dystrophy and COVID-19 cytokine storm. The results will provide insights into its ongoing projects and future direction.
Capricor Therapeutics announced positive outcomes from the HOPE-2 trial for CAP-1002, demonstrating significant improvements in Duchenne muscular dystrophy (DMD) patients. The trial met its primary efficacy endpoint of mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01), with additional positive results in skeletal and cardiac functions. CAP-1002 slowed the decline of muscle function by 71% over one year, with significant cardiac improvements (p=0.002). The findings were presented at the World Muscle Society Annual Meeting, indicating potential for advancing into pivotal trials.
Capricor Therapeutics (NASDAQ: CAPR) announced that CEO Linda Marbán, Ph.D., will present at two upcoming conferences: the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021, from 9:20 to 9:50 a.m. (ET) and the Cell & Gene Meeting on the Mesa on October 13, 2021, from 3:30 to 3:45 p.m. (PT) in Carlsbad, CA. Capricor focuses on developing transformative cell and exosome-based therapeutics, including its lead candidate CAP-1002, currently in clinical trials for Duchenne muscular dystrophy and COVID-19 treatment.
Capricor Therapeutics (NASDAQ: CAPR) will present at the 23rd Annual Global Investment Conference hosted by H.C. Wainwright from September 13-15, 2021. The company's CEO, Linda Marbán, Ph.D., will deliver an on-demand presentation available starting 7:00 a.m. ET on September 13. An archived version will be accessible post-conference on Capricor's website. Additionally, management plans to hold one-on-one meetings with institutional investors during the event.
Capricor focuses on cell and exosome-based therapeutics for various diseases, including its lead candidate, CAP-1002, targeting Duchenne muscular dystrophy and COVID-19.
Capricor Therapeutics (NASDAQ: CAPR) is set to present final data from its HOPE-2 clinical trial for CAP-1002 at the World Muscle Society Virtual Congress on Sept. 24, 2021. The trial focused on late-stage Duchenne muscular dystrophy (DMD) with 80% of participants being non-ambulant. CEO Dr. Linda Marbán expressed optimism about the data supporting CAP-1002's role in DMD treatment. The trial involved 20 patients across nine U.S. sites, and the session is scheduled from 4:15 to 5 p.m. BST (11:15 a.m. to 12 p.m. EST).